All In Biotech

Drug Trial Radar · NCT04313023

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

Last checked: Nov 19, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

217

Actual

Start

Jun 9, 2020

Primary completion

Jul 31, 2021

Study completion Jul 31, 2021

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
Collaborators
United States Department of Defense
First posted
Mar 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.

Conditions

  • COVID-19

Interventions

  • PUL-042 Inhalation SolutionDrug

    20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution

  • PlaceboDrug

    Sterile saline for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of Experimental Therapy.Time frame: 28 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California

  • Premier Urgent Care of California

    San Bernardino, California

  • Clinical Research of South Florida Alliance for Multispecialty Research

    Coral Gables, Florida

  • Invesclinic US LLC

    Fort Lauderdale, Florida

  • Luminous Cinical Research- South Florida Urgent Care

    Miami, Florida

  • Entrust Clinical Research

    Miami, Florida

  • DBC Research

    Tamarac, Florida

  • Affinity Clinical Research, LLC

    Tampa, Florida

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Willis-Knighton Physcian Network

    Bossier City, Louisiana

  • Ascension St John

    Bartlesville, Oklahoma

  • Ascension St. John

    Tulsa, Oklahoma

  • Invesclinic US LLC

    Edinburg, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Next Level Urgent Care

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.